
Mary Chebib

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/576407/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Flavonoid modulation of GABA _A receptors. British Journal of Pharmacology, 2011, 163, 234-245.	2.7	192
2	The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. Pharmacological Research, 2017, 119, 358-370.	3.1	164
3	Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochemical Pharmacology, 2009, 78, 693-702.	2.0	132
4	The dietary flavonoids apigenin and (â^')-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABAA receptors. Biochemical Pharmacology, 2004, 68, 1631-1638.	2.0	129
5	GABA A Receptors and the Diversity in their Structure and Pharmacology. Advances in Pharmacology, 2017, 79, 1-34.	1.2	119
6	Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia, 2019, 60, 2224-2234.	2.6	103
7	The Flavonoid Glycosides, Myricitrin, Gossypin and Naringin Exert Anxiolytic Action in Mice. Neurochemical Research, 2009, 34, 1867-1875.	1.6	94
8	α4βδ GABA _A receptors are high-affinity targets for γ-hydroxybutyric acid (GHB). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13404-13409.	3.3	87
9	Modulation of Ionotropic GABA Receptors by Natural Products of Plant Origin. Advances in Pharmacology, 2006, 54, 285-316.	1.2	80
10	Novel, Potent, and Selective GABA _C Antagonists Inhibit Myopia Development and Facilitate Learning and Memory. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 448-457.	1.3	71
11	Oxytocin prevents ethanol actions at δ subunit-containing GABA _A receptors and attenuates ethanol-induced motor impairment in rats. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3104-3109.	3.3	70
12	Methyllycaconitine analogues have mixed antagonist effects at nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2005, 13, 4565-4575.	1.4	61
13	Antidepressant, Anxiolytic and Antinociceptive Activities of Constituents from Rosmarinus Officinalis. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 448.	0.9	60
14	Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS ONE, 2016, 11, e0157700.	1.1	59
15	Potency of GABA at human recombinant GABAA receptors expressed in Xenopus oocytes: a mini review. Amino Acids, 2013, 44, 1139-1149.	1.2	58
16	The enantiomers of syn-2,3-difluoro-4-aminobutyric acid elicit opposite responses at the GABA _C receptor. Chemical Communications, 2012, 48, 829-831.	2.2	51
17	Innate Immunity and Inflammation Post-Stroke: An α7-Nicotinic Agonist Perspective. International Journal of Molecular Sciences, 2015, 16, 29029-29046.	1.8	51
18	GABAA Receptors Containing 🛿 Subunits Contribute to In Vivo Effects of Ethanol in Mice. PLoS ONE, 2014, 9, e85525.	1.1	50

#	Article	IF	CITATIONS
19	Flavan-3-ol derivatives are positive modulators of GABAA receptors with higher efficacy for the α2 subtype and anxiolytic action in mice. Neuropharmacology, 2008, 55, 900-907.	2.0	49
20	Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapinâ $\in \mathbb{Q}$. British Journal of Pharmacology, 2011, 163, 1017-1033.	2.7	49
21	2′â€Methoxyâ€6â€methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA _A receptors. British Journal of Pharmacology, 2012, 165, 880-896.	2.7	44
22	Stabilization of Zwitterions in Solution:  γ-Aminobutyric Acid (GABA). Journal of Physical Chemistry A, 2004, 108, 203-211.	1.1	42
23	GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators. European Journal of Medicinal Chemistry, 2019, 171, 434-461.	2.6	41
24	Flumazenil-independent positive modulation of γ-aminobutyric acid action by 6-methylflavone at human recombinant α1β2γ2L and α1β2 GABAA receptors. European Journal of Pharmacology, 2004, 491, 1-8.	1.7	40
25	GABAâ€∔receptors: distinctive functions and molecular pharmacology. British Journal of Pharmacology, 2017, 174, 1881-1894.	2.7	39
26	Galantamine is not a positive allosteric modulator of human α4β2 or α7 nicotinic acetylcholine receptors. British Journal of Pharmacology, 2018, 175, 2911-2925.	2.7	38
27	3-Hydroxy-2′-methoxy-6-methylflavone: A potent anxiolytic with a unique selectivity profile at GABAA receptor subtypes. Biochemical Pharmacology, 2011, 82, 1971-1983.	2.0	37
28	Low nanomolar GABA effects at extrasynaptic α4β1/β3Î′ GABAA receptor subtypes indicate a different binding mode for GABA at these receptors. Biochemical Pharmacology, 2012, 84, 549-557.	2.0	37
29	6-Methylflavanone, a more efficacious positive allosteric modulator of γ-aminobutyric acid (GABA) action at human recombinant α2β2γ2L than at α1β2γ2L and α1β2 GABAA receptors expressed in Xenopus oo European Journal of Pharmacology, 2005, 512, 97-104.	cytæs.	36
30	A pharmacological assessment of agonists and modulators at α4β2γ2 and α4β2Î′ GABA A receptors: The challenge in comparing apples with oranges. Pharmacological Research, 2016, 111, 563-576.	3.1	35
31	Presence of multiple binding sites on α9α10 nAChR receptors alludes to stoichiometric-dependent action of the α-conotoxin, Vc1.1. Biochemical Pharmacology, 2014, 89, 131-140.	2.0	34
32	Interactions of Flavonoids with Ionotropic GABA Receptors. Advances in Pharmacology, 2015, 72, 189-200.	1.2	34
33	Zolpidem is a potent stoichiometry-selective modulator of $\hat{1}\pm1\hat{1}^23$ GABAA receptors: evidence of a novel benzodiazepine site in the $\hat{1}\pm1\cdot\hat{1}\pm1$ interface. Scientific Reports, 2016, 6, 28674.	1.6	34
34	Gain-of-function variants in <i>GABRD</i> reveal a novel pathway for neurodevelopmental disorders and epilepsy. Brain, 2022, 145, 1299-1309.	3.7	34
35	GABA-A Receptor Modulation and Anticonvulsant, Anxiolytic, and Antidepressant Activities of Constituents from <i>Artemisia indica</i> Linn. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-12.	0.5	32
36	Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British Journal of Pharmacology, 2021, 178, 4826-4841.	2.7	32

#	Article	IF	CITATIONS
37	Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nature Communications, 2022, 13, 1822.	5.8	32
38	GABAA receptor modulation and neuropharmacological activities of viscosine isolated from Dodonaea viscosa (Linn). Pharmacology Biochemistry and Behavior, 2015, 136, 64-72.	1.3	30
39	Novel Cyclic Phosphinic Acids as GABA _C ï•Receptor Antagonists: Design, Synthesis, and Pharmacology. ACS Medicinal Chemistry Letters, 2011, 2, 11-16.	1.3	27
40	An improved, versatile synthesis of the GABAC antagonists (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) and (piperidin-4-yl)methylphosphinic acid (P4MPA). Journal of the Chemical Society, Perkin Transactions 1, 2001, , 2389-2392.	1.3	25
41	Engineered α4β2 nicotinic acetylcholine receptors as models for measuring agonist binding and effect at the orthosteric low-affinity α4–α4 interface. Neuropharmacology, 2015, 92, 135-145.	2.0	23
42	High and low GABA sensitivity α4β2δ GABAA receptors are expressed in Xenopus laevis oocytes with divergent stoichiometries. Biochemical Pharmacology, 2016, 103, 98-108.	2.0	23
43	Guanidino Acids Act as 🖥 GABAC Receptor Antagonists. Neurochemical Research, 2009, 34, 1704-1711.	1.6	22
44	Design, Synthesis, and Pharmacological Evaluation of Fluorescent and Biotinylated Antagonists of ï ₁ GABA _C Receptors. ACS Medicinal Chemistry Letters, 2013, 4, 402-407.	1.3	22
45	Modulation of Ionotropic GABA Receptors by 6-Methoxyflavanone and 6-Methoxyflavone. Neurochemical Research, 2014, 39, 1068-1078.	1.6	22
46	Gain-of-function <i>GABRB3</i> variants identified in vigabatrin-hypersensitive epileptic encephalopathies. Brain Communications, 2020, 2, fcaa162.	1.5	21
47	Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic. Journal of Biological Chemistry, 2019, 294, 6157-6171.	1.6	20
48	Convulsant actions of calycanthine. Toxicology and Applied Pharmacology, 2003, 190, 58-64.	1.3	19
49	The Z-Drugs Zolpidem, Zaleplon, and Eszopiclone Have Varying Actions on Human GABAA Receptors Containing γ1, γ2, and γ3 Subunits. Frontiers in Neuroscience, 2020, 14, 599812.	1.4	19
50	Ligand Binding at the α4-α4 Agonist-Binding Site of the α4β2 nAChR Triggers Receptor Activation through a Pre-Activated Conformational State. PLoS ONE, 2016, 11, e0161154.	1.1	18
51	The flavonoid, 2′-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1266-1282.	2.4	18
52	Covalent Trapping of Methyllycaconitine at the α4-α4 Interface of the α4β2 Nicotinic Acetylcholine Receptor. Journal of Biological Chemistry, 2013, 288, 26521-26532.	1.6	17
53	A pharmacological characterization of GABA, THIP and DS2 at binary α4β3 and β3δ receptors: GABA activates β3δ receptors via the β3(+)δ(â~) interface. Brain Research, 2016, 1644, 222-230.	1.1	17
54	Pinnatoxins E, F and G target multiple nicotinic receptor subtypes. Journal of Neurochemistry, 2015, 135, 479-491.	2.1	15

#	Article	IF	CITATIONS
55	The Direct Actions of GABA, 2'-Methoxy-6-Methylflavone and General Anaesthetics at β3γ2L GABAA Receptors: Evidence for Receptors with Different Subunit Stoichiometries. PLoS ONE, 2015, 10, e0141359.	1.1	14
56	Novel Approach for the Search for Chemical Scaffolds with Activity at Both Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptor: A Perspective on Scaffolds with Dual Activity for the Treatment of Neurodegenerative Disorders. Molecules, 2019, 24, 446.	1.7	13
57	Covalent attachment of antagonists to the α7 nicotinic acetylcholine receptor: synthesis and reactivity of substituted maleimides. Chemical Communications, 2012, 48, 6699.	2.2	12
58	Concatenated Î ³ -aminobutyric acid type A receptors revisited: Finding order in chaos. Journal of General Physiology, 2019, 151, 798-819.	0.9	12
59	Identifying the Binding Site of Novel Methyllycaconitine (MLA) Analogs at α4β2 Nicotinic Acetylcholine Receptors. ACS Chemical Neuroscience, 2010, 1, 796-809.	1.7	11
60	(3-Aminocyclopentyl)methylphosphinic acids: Novel GABAC receptor antagonists. Neuropharmacology, 2007, 52, 779-787.	2.0	10
61	Comparison of templates for homology model of il GABA C receptors: More insights to the orthosteric binding site's structure and functionality. Journal of Molecular Graphics and Modelling, 2015, 62, 43-55.	1.3	10
62	Revisiting autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) mutations in the nicotinic acetylcholine receptor reveal an increase in efficacy regardless of stochiometry. Pharmacological Research, 2019, 139, 215-227.	3.1	10
63	Delta-containing GABAA receptors in pain management: Promising targets for novel analgesics. Neuropharmacology, 2021, 195, 108675.	2.0	10
64	Targeting GABAC Receptors Improves Post-Stroke Motor Recovery. Brain Sciences, 2021, 11, 315.	1.1	8
65	Regional Fos-expression induced by γ-hydroxybutyrate (GHB): Comparison with γ-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. Neuroscience, 2014, 277, 700-715.	1.1	7
66	The Synthesis and Evaluation of Fluoroâ€; Trifluoromethylâ€; and Iodomuscimols as GABA Agonists. Chemistry - A European Journal, 2017, 23, 10848-10852.	1.7	7
67	Investigating the Role of Loop C Hydrophilic Residue â€~T244' in the Binding Site of il GABAC Receptors via Site Mutation and Partial Agonism. PLoS ONE, 2016, 11, e0156618.	1.1	7
68	GABA _A receptors: Various stoichiometrics of subunit arrangement in α1β3 and α1β3ε receptors. Current Pharmaceutical Design, 2018, 24, 1839-1844.	0.9	7
69	Efficient expression of concatenated α1β2δand α1β3Ĩ´GABA _A receptors, their pharmacology and stoichiometry. British Journal of Pharmacology, 2021, 178, 1556-1573.	2.7	6
70	The de novo <i>GABRA4</i> p.Thr300lle variant found in a patient with earlyâ€onset intractable epilepsy and neurodevelopmental abnormalities displays gainâ€ofâ€function traits. Epilepsia, 2022, 63, 2439-2441.	2.6	6
71	AE Succinimide, an Analogue of Methyllycaconitine, When Bound Generates a Nonconducting Conformation of the α4β2 Nicotinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2020, 11, 344-355.	1.7	3
72	Ligand-gated ion channels in genetic disorders and the question of efficacy. International Journal of Biochemistry and Cell Biology, 2020, 126, 105806.	1.2	3

#	Article	IF	CITATIONS
73	The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations. Neuropharmacology, 2021, 182, 108371.	2.0	3
74	Roles of hydrophilic residues in GABA binding site of GABA-Ïl receptor explain the addition/inhibition effects of competitive ligands. Neurochemistry International, 2022, 153, 105258.	1.9	3
75	Novel methyllycaconitine analogues selective for the α4β2 over α7 nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2021, 51, 116516.	1.4	2
76	Pharmacological Effect of GABA Analogues on GABA-ϱ2 Receptors and Their Subtype Selectivity. Life, 2022, 12, 127.	1.1	2
77	Role of Aβ and the α7 nicotinic acetylcholine receptor in regulating synaptic plasticity in Alzheimer's disease. International Journal of Peptide Research and Therapeutics, 2003, 10, 401-404.	0.1	1
78	Role of A β and the α 7 nicotinic acetylcholine receptor in regulating synaptic plasticity in Alzheimer's disease. International Journal of Peptide Research and Therapeutics, 2003, 10, 401-404.	0.9	0
79	A Hydrophobic Area of the GABA 🕯 Receptor Containing Phenylalanine 124 Influences Both Receptor Activation and Deactivation. Journal of Molecular Neuroscience, 2015, 55, 305-313.	1.1	0
80	Optimising the transient expression of GABA(A) receptors in adherent HEK293 cells. Protein Expression and Purification, 2019, 154, 7-15.	0.6	0